Experts discuss 2 cases on second-line management of advanced NSCLC with immune checkpoint inhibitors.
This activity is intended for hematologists/oncologists, pulmonologists, pathologists, and nurses.
Approximate Time to Complete: 30 minutes
Credit Available: Jan. 31st, 2019- Jan. 31st, 2020
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding clinical trial data on the use of ICIs alone or in combination in second-line management of advanced NSCLC
- Have greater competence related to identifying patients with advanced NSCLC who may benefit from the use of ICIs
- Have greater competence related to team-based management of irAEs in patients with advanced NSCLC